Science for Patients’ Sake

"Science is not the main goal but a means to an end. We wish to be known primarily for our contributions to patients, not science."

Wim Dokter , Byondis Chief Scientific Officer

Nothing excites Byondis scientists more than the translation of science into clinical practice that improves patient standard of care. For the last 10 years, we have been employing the latest insights in tumor biology and immunology to create next generation precision therapies: antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs) and new chemical entities that can stand alone or be incorporated in our ADCs.

ADCs are the cornerstone of our R&D efforts. They target difficult-to-treat cancers with powerful cytotoxins and offer a wider therapeutic window and lower systemic toxicity. These therapies are based on our distinctive, proprietary linker-drug technologies, novel mechanisms of action, and selected combination strategies.

Currently, our lead ADC, [vic-]trastuzumab duocarmazine (SYD985), is undergoing regulatory review in the U.S. and EU in HER2-positive metastatic breast cancer. SYD985 is also being explored in other clinical indications, such as HER2-expressing metastatic endometrial cancers.

We are expanding our pipeline of ADC therapies. BYON3521, an ADC that targets c-MET, is currently in a First-in-Human (Phase I) study. c-MET is widely overexpressed in a variety of solid tumors, including renal cell cancer, uveal (ocular) melanoma, non-small cell lung cancer and head and neck squamous cell cancer. Another ADC, BYON4413, is preparing to enter Phase I study later this year. This ADC is directed against CD123, expressed in Acute Myeloid Leukemia (AML) and other hemato-oncological malignancies.

Our lead cancer immunotherapeutic, BYON4228, will also enter Phase I study this year. BYON4228 has potential across a range of cancer indications, in combination with other cancer therapies, including anticancer antibodies, ADCs, checkpoint inhibitors or conventional cancer drugs.

In our early discovery pipeline, three new platforms have been identified: a novel linker-drug technology to generate IO ADCs; a linker-drug technology to generate ADCs with potential in both oncologic and other indications, such as autoimmune diseases; and a platform to increase the tumor-specificity of mAbs and ADCs.

Byondis collaborates with other global biotechnology and pharmaceutical companies, as well as many leading academic research institutions. While uniquely positioned to take our innovative portfolio beyond the laboratory, up to and including pivotal clinical studies, we welcome partners and collaborators to help speed the development of our medicines and provide access for those patients who need them.

We call this “making hope real.”